Results 231 to 240 of about 169,027 (313)

Basophil Activation and Histamine Release Tests in Relation to Omalizumab Response in Peanut‐Allergic Children

Clinical &Experimental Allergy, EarlyView.
Christian Nielsen, Per Stahl Skov, Carsten Bindslev‐Jensen, Charlotte G. Mortz   +3 more
wiley   +1 more source

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Data from 2731 patients with hidradenitis suppurativa (HS) treated with biologics for 12–16 weeks in phase III randomized controlled trials (RCT) were included in a network meta‐analysis (NMA). Adalimumab showed the highest efficacy in achieving a clinical HS response 50 (HiSCR50) and the lowest incidence of adverse events (AE).
Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, Lars E. French, Benjamin Kendziora   +4 more
wiley   +1 more source

Clinical Scaleup of Humanized AnnA1 Antibody Yielded Unexpected High Reticuloendothelial (RES) Uptake in Mice. [PDF]

Antibodies (Basel)
Xu LL, Singh SK, Nayback C, Metebi A, Agnew D, Buss T, Schnitzer J, Zinn KR.   +7 more
europepmc   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Evaluating the immune effector functions induced by humanized anti-CD99 antibody in eliminating T lymphoblastic leukemia/lymphoma cells. [PDF]

Discov Oncol
Kotemul K, Chaiwut R, Putpim C, Pata S, Laopajon W, Tayapiwatana C, Kasinrerk W, Takheaw N.   +7 more
europepmc   +1 more source

Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer. [PDF]

Cells
Shih CH, Hsieh TY, Sung WW.
europepmc   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

Periodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva, Jennifer Malcolm, Shauna Culshaw   +2 more
wiley   +1 more source

Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine. [PDF]

Animals (Basel)
Wang J, Zhou X, Elazab ST, Huang J, Hsu WH.   +4 more
europepmc   +1 more source

Updated insights into the molecular pathogenesis of canine atopic dermatitis

Veterinary Dermatology, EarlyView.
Abstract Atopic dermatitis (AD) is a common and chronic inflammatory skin disease with frequent relapses. The genomics revolution has greatly contributed and revolutionised our knowledge of human AD; understanding the molecular skin fingerprint of AD and associated pathogenic immune pathways has led to preclinical assessments of several novel ...
Frane Banovic
wiley   +1 more source

Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report. [PDF]

BMC Neurol
Kohandel K, Ala S, Tamizifar B, Karaminia M, Sahraian M.   +4 more
europepmc   +1 more source